Christopher B. Ehrlich - 07 Jan 2026 Form 4 Insider Report for CERO THERAPEUTICS HOLDINGS, INC. (CERO)

Reporting relationship
Chairman and CEO, Director
Issuer ticker
CERO
Reported as of
07 Jan 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
09 Jan 2026, 16:30:15 UTC
Prior SEC filing
02 Jun 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Andrew Kucharchuk, Attorney-in-Fact

Key filing fact

Christopher B. Ehrlich filed Form 4 for CERO THERAPEUTICS HOLDINGS, INC. (CERO) on 09 Jan 2026.

Key facts

  • This page summarizes Christopher B. Ehrlich's Form 4 filing for CERO THERAPEUTICS HOLDINGS, INC. (CERO).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 09 Jan 2026, 16:30.

Change

  • Previous filing in this sequence was filed on 02 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001293973 Primary reporting owner

Ehrlich Christopher B

Relationship
Chairman and CEO, Director
Address
CERO THERAPEUTICS HOLDINGS, INC., 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO
Signature
/s/ Andrew Kucharchuk, Attorney-in-Fact
Signature date
09 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CERO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+4,530,997
Change %
Price
$0.000000
Shares after
4,530,997
Date
07 Jan 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,530,997
Exercise price
$0.0550
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .